{"schema_version":"secwatch.filing_event.v1","accession":"0001387131-23-006742","form_type":"8-K","ticker":null,"cik":"0000887247","company_name":"DMK PHARMACEUTICALS Corp","filed_at":"2023-05-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.632548+00:00","generated_at":"2026-06-14T18:57:53.751591+00:00","sec_items":["3.03","5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Adamis Pharmaceuticals effects 1-for-70 reverse stock split to regain Nasdaq compliance","bullets":["Reverse split effective 12:01 a.m. ET on May 22, 2023; shares begin trading split-adjusted same day.","Ratio of 1-for-70 approved by board after shareholders authorized range of 1-for-2 to 1-for-100.","Purpose: increase stock price to meet Nasdaq minimum $1.00 bid for 10 consecutive days by June 26, 2023.","Split also a closing condition of the previously announced merger with DMK Pharmaceuticals.","No change to authorized shares (200M common); CUSIP changes to 00547W 307; symbol remains ADMP."],"urls":{"canonical":"https://secwatch.observer/filing/0001387131-23-006742","json":"https://secwatch.observer/filing/0001387131-23-006742.json","markdown":"https://secwatch.observer/filing/0001387131-23-006742.md","text":"https://secwatch.observer/filing/0001387131-23-006742.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/887247/000138713123006742/0001387131-23-006742-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/887247/000138713123006742/admp-8k_052223.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T18:57:53.751591+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8befb03221ad12b46e02b634b5934ab131e44d8c","claim":"DMK PHARMACEUTICALS Corp: The company filed a Certificate of Amendment to its Restated Certificate of Incorporation to effect a 1-for-70 reverse stock split of its common stock, effective 12:01 a.m. Eastern time (effective 2023-05-22).","evidence_excerpt":"Adamis Pharmaceuticals Corporation (the “Company”) filed a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Restated Certificate of Incorporation (the “Restated Certificate”) with the Secretary of State of Delaware, effective 12:01 a.m. Eastern time, to effect a 1-for-70 reverse stock split of the outstanding shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) (the “Reverse Stock Split”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/887247/000138713123006742/0001387131-23-006742-index.htm","confidence":0.95,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-05-22"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}